Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

F-Star Therapeutics Inc (FSTX)

F-Star Therapeutics Inc (FSTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 156,512
  • Shares Outstanding, K 21,982
  • Annual Sales, $ 21,170 K
  • Annual Income, $ -31,280 K
  • 60-Month Beta 0.85
  • Price/Sales 7.16
  • Price/Cash Flow N/A
  • Price/Book 2.75
Trade FSTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.82
  • Most Recent Earnings $-0.84 on 11/10/22
  • Latest Earnings Date 03/13/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.67
  • Prior Year 0.47
  • Growth Rate Est. (year over year) -217.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.50 +58.22%
on 02/09/23
7.12 unch
on 03/08/23
+2.70 (+61.09%)
since 02/08/23
3-Month
2.99 +138.13%
on 01/26/23
7.12 unch
on 03/08/23
+1.80 (+33.83%)
since 12/08/22
52-Week
2.07 +243.96%
on 05/12/22
7.12 unch
on 03/08/23
+4.22 (+145.94%)
since 03/08/22

Most Recent Stories

More News
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

BNGO : 0.7611 (-4.19%)
FSTX : 7.12 (unch)
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

invoX Pharma Limited (“invoX”) , a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today...

FSTX : 7.12 (unch)
Earnings Preview: Fstar Therapeutics, Inc. (FSTX) Q3 Earnings Expected to Decline

Fstar Therapeutics, Inc. (FSTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FSTX : 7.12 (unch)
BLUE : 0.9229 (-4.91%)
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 2.61% and 97.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

CRSP : 55.65 (-1.35%)
FSTX : 7.12 (unch)
F-STAR THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

FSTX : 7.12 (unch)
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License...

FSTX : 7.12 (unch)
invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.

invoX Pharma Limited (“invoX”) , a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) , focused on research and development (R&D) and business development...

FSTX : 7.12 (unch)
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and ZEN Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

FSTX : 7.12 (unch)
STCN : 12.14 (+0.58%)
ZEN : 77.48 (+0.03%)
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating...

FSTX : 7.12 (unch)
F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of F-star Therapeutics, Inc. (NasdaqCM: FSTX)...

FSTX : 7.12 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 7.13
2nd Resistance Point 7.13
1st Resistance Point 7.12
Last Price 7.12
1st Support Level 7.11
2nd Support Level 7.11
3rd Support Level 7.10

See More

52-Week High 7.12
Last Price 7.12
Fibonacci 61.8% 5.19
Fibonacci 50% 4.59
Fibonacci 38.2% 4.00
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar